药物涂层球囊在下肢动脉硬化闭塞症腔内治疗中的应用进展  

Progress of drug-coated balloons in endovascular treatment of lower extremity arteriosclerosis obliterans

作　　者：晏燕(综述) 韩鹏(审校)[1] 刘冰(审校)[1] YAN Yan;HAN Peng;LIU Bing(Department of Vascular Surgery,First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院血管外科,哈尔滨150001

出　　处：《临床与病理杂志》2021年第11期2706-2711,共6页Journal of Clinical and Pathological Research

摘　　要：外周动脉疾病被认为是导致截肢的主要原因,血管内介入技术目前已经成为解决这类疾病的主要手段。下肢病变情况多较复杂,支架内再狭窄仍然是腔内治疗面临的棘手问题。药物涂层球囊通过靶向输送药物抑制内膜增生,在下肢股腘动脉、膝下动脉、支架内再狭窄病变中都得到了广泛应用。因在血管腔内不留任何金属等置入物,改善了支架内再狭窄问题治疗的现状,但随之带来的一系列安全性问题也引发广泛关注。Peripheral arterial disease(PAD)involving the lower extremity is a major source of morbidity and mortality.Endovascular interventions technology has become the main way to solve this kind of disease.The lesions of the lower extremity are more complex,and the management of patients with in-stent restenosis(ISR)remains challenging.Drug coated balloons(DCB)inhibit intimal hyperplasia by targeting drug delivery and have been used not only in femoral popliteal artery,and infrapopliteal artery,but also the aspect of ISR.There is no metal or other implants left in the vascular lumen,which improves the current situation of treatment of ISR,but a series of safety problems also cause wide concern.

关 键 词：药物涂层球囊 股腘病变 膝下病变 支架内再狭窄 紫杉醇 安全性 

分 类 号：R54[医药卫生—心血管疾病]